Why TRT, and why the build is different
Men's testosterone is the classic longitudinal telehealth category: a patient who feels bad enough to act, a diagnosis anchored in a lab value, and a therapy that runs for years when it is managed well. The big men's-health brands proved the demand at national scale. The opportunity in 2026 is running the category better than a funnel-first operation can.
But TRT punishes teams that treat it like a wellness SKU. Two structural facts shape everything: the diagnosis requires blood work you cannot skip, and testosterone is a Schedule III controlled substance, which pulls your program into DEA territory that most telehealth verticals never touch.
One scope note before the playbook: this post covers men's TRT. Women's testosterone is a different program with different dosing, sourcing, and positioning, and we covered it in Women's Testosterone: The Fastest-Growing Hormone Niche, Served Responsibly.
Updated September 22, 2026: retitled, added the DEA status as of September (Special Registration final rule at OIRA since August 25, flexibilities through December 31), the Q2 signals from Hims and LifeMD, a software table, and two FAQ answers.
The market signal, September 2026
Two public-company data points settle the demand question. On its Q2 2026 call on August 10, Hims & Hers said testosterone is approaching a $100 million annualized run-rate, inside a $753.2 million quarter (up 38 percent) at a 64 percent gross margin, down from 76 percent on the move to branded drugs. On August 5, LifeMD announced a co-marketing agreement for XYOSTED, the subcutaneous testosterone enanthate autoinjector. Both are building on FDA-approved formulations. Neither runs a labs-forward program with named clinicians for one community; that is the independent clinic's lane.
Labs first: the intake that starts with a blood draw
A TRT program cannot ethically or legally diagnose hypogonadism from a symptom quiz. Standard practice requires confirmed low testosterone, typically two morning blood draws, plus a workup that rules out causes a prescription would mask. That means your funnel has a lab step between lead and prescription, and the design question is where to put it so it qualifies patients instead of losing them.
The strongest pattern we see: sell the diagnostic first. The entry purchase is a lab panel with a clinician review, not a testosterone subscription. It sets honest expectations, filters the patients who were never candidates, and gives the provider real data on day one. The mechanics of keeping patients moving between lab order, draw, result, and review are their own discipline, and we wrote them up in Telehealth Lab Workflow Design.
Then the cadence continues for the life of the subscription:
| Stage | When | What gets checked | Why it matters |
|---|---|---|---|
| Baseline | Before any prescription | Two morning total testosterone draws, plus workup per your protocol | Confirms the diagnosis and rules out causes that need different care |
| First recheck | 6-8 weeks after starting | Testosterone level, hematocrit, symptom review | Confirms dosing direction and catches early red flags |
| Periodic monitoring | Then on a recurring schedule per protocol | Levels, hematocrit, and the safety panel your medical director defines | Keeps long-term therapy safe and keeps the refill defensible |
The exact panel contents and intervals belong to your medical director, written into protocol before patient one, the same discipline we argued for in Clinical Protocols for DTC Telehealth. The operator's job is different: make sure every stage in that table has an owner, an automated reminder, and a blocking rule so a refill cannot ship past a missed monitoring window.
That blocking rule is the heart of the build. In a well-run TRT program, labs gate refills the way card authorization gates shipping.
Compliance: Schedule III changes the clock
Testosterone is Schedule III. Today, prescribing it via telehealth without a prior in-person exam rides on the DEA's temporary telehealth flexibilities, and the fourth extension runs through December 31, 2026. The proposed Special Registration framework that would replace the flexibilities is still not final, and as written it would require covered online platforms to hold their own special registration, not just the prescribers. We unpacked what to build under the current rules in DEA Telehealth Flexibilities: What Programs Should Build Now.
For a TRT launch in 2026, that means three concrete workstreams:
Prescriber registration hygiene. Every prescribing clinician needs the right DEA registration for every state they prescribe into, tracked as licensing data, not tribal knowledge.
State wrinkles on top of federal. States layer their own rules on controlled-substance telehealth: some require a prescription monitoring program check before each script, some restrict which encounter types qualify, a few effectively require an in-person visit regardless of federal flexibility. Sequence your state rollout with the strict states later, and put the state rules in your routing logic, not in a PDF.
A December 31 contingency. Any program built on the flexibilities needs a written plan for the rule finalizing, extending, or lapsing. We published that plan as the DEA cliff 120-day contingency plan; the summary is: know which of your patients would need an in-person exam under a lapse, and know how you would get them one.
None of this is a reason to avoid the category. It is a reason the category still has room in it: the compliance work is a moat exactly because most wellness operators will not do it.
DEA status as of September 2026
The fourth extension of the telemedicine flexibilities, published in the Federal Register on December 31, 2025, runs through December 31, 2026. The Special Registration final rule went to OIRA on August 25, 2026, and DOJ's forecasts point to publication around November (NASCSA, September 21). No fifth extension has been announced.
The January 2025 proposal had three registrations: Telemedicine Prescribing (Schedule III-V), Advanced Telemedicine Prescribing (Schedule II-V), and a Telemedicine Platform registration for the sites that host the prescribing. Testosterone is Schedule III, so a TRT clinic's clinicians would sit in the base tier and the platform could need its own registration; we plan as if the final rule keeps that tier. The scenario-by-scenario build is in the 120-day contingency plan.
Software an online TRT clinic needs
The clinic is a workflow with a blood draw in the middle of it, so the software has to sequence labs, providers, billing, and pharmacy in that order.
| Capability | Turbopills covers | You bring |
|---|---|---|
| Labs-first intake branching | Conditional intake that blocks the prescription path until baseline draws are on file | Eligibility and refusal criteria (medical director) |
| Lab ordering and results | Lab step in the workflow; results as discrete values in chart and portal | Lab partner and panel contents |
| State-aware provider routing | Each case sent to a clinician licensed in the patient's state | Your professional entity and its DEA-registered clinicians |
| Controlled-substance e-prescribing readiness | Order and record flow; EPCS itself runs in your prescribers' certified e-prescribing tool | Prescriber DEA registrations, PDMP process |
| Subscriptions with retries | Bundle billed only after clinical approval, on your own gateway accounts, with retries and dunning | Merchant account |
| Pharmacy routing | Injectable, gel, or oral testosterone from the pharmacy you choose, with order status | Pharmacy choice and contract |
| Patient portal for results and dosing | Branded portal with lab trends, check-ins, dosing instructions, refill requests | Plain-language result explanations |
The Turbopills column ships as one system with a GraphQL API behind it and launches in weeks. We are in private beta and quote pricing per program; verify every row in a demo against your own protocol.
The economics: what a $100-200 bundle has to carry
Most DTC TRT programs price as a flat monthly subscription in the $100-200 range, bundling the medication, provider oversight, and some or all of the recurring labs. The bundle is the right structure: it turns monitoring from an upsell into an included feature, which is better medicine and better retention.
The margin math has to carry four recurring costs: medication and fulfillment, lab panels at protocol cadence, provider time for reviews and titration visits, and support. Two design choices protect it. First, price the baseline diagnostic separately from the subscription, so acquisition cost is not compounded by lab cost on patients who never convert. Second, meter the provider touch: asynchronous data review for stable patients on schedule, synchronous visits reserved for titration decisions and flags.
Because the economics are subscription economics, everything we know about telehealth retention applies, and TRT holds a structural advantage: stopping therapy means symptoms return. Patients rarely churn out of TRT because they feel done. They churn because the program felt disorganized, a refill stalled, a lab request came as a surprise, or nobody explained what the numbers meant. All of that is operational, which means all of it is fixable.
Retention is titration plus visibility
The retention loop in TRT is clinical, not promotional. The first 90 days decide the next three years, and the levers are:
Symptom tracking that shows the trend. Energy, sleep, mood, libido, training performance: a simple recurring check-in that charts alongside lab values gives the patient proof of progress and gives the provider titration signal. The portal is where that trend lives; a patient who can see their own trajectory does not need to be convinced to renew.
Titration as a feature, not a failure. Dose adjustments in the first months are normal. Programs that frame the 6-8 week recheck as "this is how we dial you in" convert what could feel like a setback into evidence of attentive care.
Expectation-setting up front. Tell patients at intake that benefits build over weeks, that the first recheck may change their dose, and that labs are a permanent part of the deal. Surprise is the churn driver; the intake is where you remove it.
Adjacent needs, handled honestly. TRT patients overlap heavily with ED and sexual-health needs, and a program that can handle both journeys under one roof retains better than one that hands patients elsewhere. The journey mechanics are covered in ED and Sexual Health Telemedicine Programs.
Positioning against the big brands
You will not outbid the national men's-health brands on branded search, and you should not try. Their scale is also their constraint: high-volume funnels optimize for the median patient. The positions that win against them:
Be the labs-forward program. Publish your monitoring cadence and your refusal criteria. The patient who researches TRT reads plenty of skepticism about mills; being visibly rigorous converts exactly the high-LTV patient the funnels lose. This is the same trust math we laid out in Clinical Governance Is a Growth Asset.
Own a niche the giants ignore. Regional identity, an existing audience from a gym or coaching brand, a specific community. Distribution you already have beats distribution you rent.
Compete on the relationship. Named providers, real titration conversations, results explained in plain language. In a category where patients stay for years, care quality compounds in reviews, referrals, and increasingly in what AI assistants say when someone asks which TRT programs are legitimate.
On Turbopills, the TRT build is the intake with lab gating, state-aware provider routing, the subscription engine, and the patient portal carrying the symptom and lab trends. The parts you should own are the protocol and the positioning. We handle the plumbing.
FAQ
Do online TRT programs require blood work? Yes. Standard practice requires confirmed low testosterone on blood work, typically two morning draws, before prescribing, then a recheck around 6-8 weeks after starting and periodic monitoring for as long as therapy continues. A program that prescribes testosterone from a questionnaire alone is a red flag, clinically and legally.
Can testosterone be prescribed via telehealth in 2026? Yes, under the DEA's temporary telehealth flexibilities, which currently run through December 31, 2026, and subject to state-level rules that vary. The proposed Special Registration framework that would replace the flexibilities is not yet final, so programs prescribing testosterone need a contingency plan for the end of the year.
What does an online TRT subscription typically cost? Most DTC programs bundle medication, provider oversight, and recurring labs into a flat monthly subscription, commonly in the $100-200 per month range depending on formulation and what the bundle includes. The baseline diagnostic panel is usually priced separately before the subscription starts.
Are TRT clinics profitable? At scale, yes: Hims told investors on August 10, 2026 that testosterone is approaching a $100 million annualized run-rate. For an independent online clinic, the $100-200 bundle has to carry medication, labs at protocol cadence, provider time, and support; the programs that price the baseline diagnostic separately, meter provider touch, and keep patients for years clear a real margin.
How to open a TRT clinic? In order: a professional entity with a medical director who writes the protocol; a lab partner; a pharmacy for your formulation; clinicians licensed and DEA-registered in your launch states; software for labs-first intake, state-aware routing, approval-gated billing, pharmacy routing, and the portal; and a written plan for the DEA rule expected in November. On Turbopills the software launches in weeks; the protocol, the entity, and the marketing are yours.
Why do TRT programs retain patients better than other telehealth categories? Because therapy is open-ended and symptoms return if it stops, retention depends mostly on operational quality rather than motivation. Patients who see their lab values and symptom trends improving, and who never hit a refill or lab-scheduling failure, tend to stay for years.